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Purpose: Many anthracycline anticancer drugs contain carbohydrate moieties as a 
part of their chemical structure. Research studies have suggested that the sugar moiety of 
these anthracyclines play an important role in determining the biological and 
pharmacological activities of the drug. The clinical application of anthracycline 
antibiotics, daunorubicin (DNR) and doxorubicin is limited by the development of 
multidrug resistance (MDR) in cancer therapy. To overcome multidrug resistance, we 
synthesized daunorubicin derivatives with disaccharides, monosaccharide bearing azido 
(d9) and triazole groups (compounds d10-d13), monosaccharide with uncommon (DNR-
1 to DNR 6, and aglycon compound (DNR-A). Methods: The anticancer activity of these 
compounds was examined in drug-sensitive leukemia K562 cells and drug-resistant 
K562/dox cells by MTS assay. MTS in the presence and absence of CsA, a potent 
inhibitor of P-glycoprotein, were conducted to measure drug uptake and efflux mediated 
by P-gp. Results: Compounds with various terminal 2,6-dideoxy sugars (d1, d3, d5, and 
d8) showed 30 to 60-fold higher anticancer activity than compounds with terminal 2-
deoxy- or 6-deoxysugar (compound d6 and d7).  This suggests that 2”-OH or 6”-OH 
groups in terminal sugar decrease its anticancer activity. Compound (d9) with azido 
deoxysugar showed potent anticancer activity in drug-sensitive K562 cells (IC50 of 
0.075uM). Compared to DNR, compound (d9) is more active than DNR against K562 
drug-resistant cells. The drug resistance index (DRI) value of compound (d9) is 10-fold 
less than that of DNR. P-gp inhibitor CsA did not change cell killing effects of compound 
d9 at 1uM concentration, while it significantly increased DNR’s cell killing effect by 
more than 2-fold. These results indicate that compound (d9) may no longer be a P-gp 
 3
P-gp Transporters Pump out drugs from cells 
L e ss  a ccu m u la tio n  
o f a n tica n ce r d ru g s
A n tica n ce r 
D ru g s
A B C  T ra n sp o rte rs
A n tica n ce r 
D ru g s
D ru g -R e s is ta n t 
C a n ce r C e lls  
substrate and overcome P-gp mediated drug resistance. Compared to daunorubicin 
derivatives with various uncommon sugars, the aglycon compound DNR-A showed 70- 
to 100-fold lower cytotoxicity, which suggests that the sugar moiety for anthracyclines is 
important for cytotoxixity. Conclusion: Modifications of sugar structures of 
daunorubicin significantly changed its anticancer activity. Daunorubicin derivative with 
an azido in the sugar structure may avert the recognition by P-gp and overcome P-gp-
mediated drug resistance. 
INTRODUCTION 
 Anthacyclines are natural products antibiotics with potent anticancer activity. 
Doxorubicin and daunorubicin are among the first to be clinically approved in the late 
1960s and early 1970s. Doxorubicin has a wide range of anticancer activity against 
leukemia, breast cancers and sarcomas while daunorubicin is very effective in the 
treatment of leukemia. A typical problem which is facing chemotherapy is the existence 
of multidrug resistance characterized by the over-expression of P-glycoprotein (P-gp). P-
gp pumps drugs out from cancer cells, reduces intracellular cell concentration, and 







Figure 1. P-gp exports drug from cells and induces multidrug resistance   
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HYPOTHESIS 
 We hypothesize that direct modification of sugar moieties of daunorubicin may 
avert recognition by P-gp, increase drug intracellular concentration in cancer cells, and 
thus overcome drug resistance. 
MATERIALS AND METHODS 
 Analogs of daunorubicin was synthesized (D1-D8) with disaccharides of terminal 
2,6-dideoxy sugar or 2-deoxy- or 6-deoxy-sugar (Figure 2). D9 was a lead compound 
with an azido group in the sugar structure. The other analogs (D10-D13) had their 3’ 
position replaced with a larger triazole group. The cytotoxicity of the newly synthesized 
analogs of daunorubicin, was tested using MTS [3-(4,5-dimethythiazol-2-yl)]-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay in drug-sensitive 
leukemia K562  and drug- resistant K562 (K562/dox) cells, and colon cancer (SW620) 
cells. The positive control with daunorubicin and a negative control with no drugs were 
included. 
Cytotoxicity of daunorubicin analogues by MTS assay: Drug-sensitive K562 and 
drug-resistant K562/Dox cells (2,000-10,000) were seeded in 96 well plates in RPMI-
1640 and incubated for 24 hours. The exponentially growing cancer cells were incubated 
with various concentrations of compounds for 72 hours at 37 °C (5% CO2, 95% 
humidity). After 72 hours incubation, tetrazolium[3-(4,5-dimethythiazol-2-yl)]-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS, 2 mg/ml) 
and phenazine methosulfate (PMS, 25 µM) were mixed and added directly to the cells. 
After incubation for 3 hrs at 37 °C, the absorbance of formazan (the metabolite of MTS 
by viable cells) was measured at 490 nm. The IC50 values of the compounds for 
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cytotoxicity were calculated by WinNonlin software from the dose-response curves. The 
standard deviation calculated from six experimental replicates was calculated and used as 









 Daunorubicin and its analog with disaccaharide and azido group 
 
Drug resistance assay of daunorubicin analogues: K562/Dox leukemia cells (2000-10, 
000) were seeded in 96-well plates in RPMI-1640 and incubated overnight. The cells 
were pretreated with 5 µM Cyclosporine A (CsA) for 10 minutes. Then the synthesized 
compounds (1 µM) were added. After 72 hours, tetrazolium[3-(4,5-dimethythiazol-2-yl)]-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS, 2 
mg/ml) and phenazine methosulfate (PMS, 25 µM) were mixed and added directly to the 
cells. After incubated for 3 hrs at 37 °C, the absorbance of formazan (the metabolite of 
MTS by viable cells) was measured at 490 nm. The Drug Resistance Index (DRI), which 


















































































































































Figure 3. Daunorubicin analogues with uncommon sugar 
 
RESULTS AND DISCUSSION 
α- linkage between disaccharides of daunorubicin analogues provides better activity 
than β-linkage 
 
 Compound with α-linkage between two sugar units (d3) showed 35-fold higher 
anticancer activity than compound with β-linkage (d4) (Fig. 4). This indicates that α-
linkage configuration was the mostly likely preferred conformation for the sugar moiety, 










0 1 5 1 0 5 0 1 0 0 5 0 0 1 0 0 0 5 0 0 0




































Dideoxy sugar structure in daunorubicin analogues showed higher anticancer 
activity than deoxy sugars 
 
Compounds with various terminal 2,6-dideoxy sugars (d1, d3, d5, and d8) 
showed 30 to 60-fold higher anticancer activity than compounds with terminal 2-deoxy- 
or 6-deoxysugar (compound d6 and d7) (Fig. 4).  This suggests that 2”-OH or 6”-OH 
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Figure 5. Anticancer activity of Monosaccharide Daunorubicin 
 
-NH2 replacement of daunorubicin changes its activity 
When -NH2 in the primary sugar of daunorubicin changed to larger moieties with 
triazole (compound d10-d13), its anticancer activity significantly decreased by 16 to 30-
fold (Figure 5). However, when the –NH2 of daunorubicin changed to -N3 (compound 
d9), its anticancer activity slightly decreased. These data indicate that modification of the 




Table 1 Drug resistance index data. 
# IC50 in K562 
(nM) 
IC50 in K562/R 
(uM) DRI (Ratio) 
d1 39.5 2.1 53 
d2 45.8 4.6 101 
d3 44.3 3.6 81 
d5 21.0 1.3 65 
d8 31.3 2.4 79 
d9 75.4 1.0 13 
dau 15.6 2.2 139 
 
Azido group in sugar moiety of daunorubicin showed better activity against drug-































Figure 6. Anticancer activity of Daunorubicin analogs in drug resistant leukemia 
K562/dox 
 
By sugar modification, we have successfully found a lead compound (d9) to 
overcome drug resistance. Its activity was tested in drug-resistant leukemia cells 
(K562/R). These cells have expressed 4 to 1000- fold higher P-gp expressions compared 
to parent drug-sensitive cancer cells. Compound d1, d5, and d9 showed improvements in 
overcoming drug resistance. Their drug resistance index (DRI, ratio of IC50 in drug-
resistant cells over IC50 in drug-sensitive cells) decreased by more than 2 to 10-fold 
compared to daunorubicin (Table 1, Figure 6). Very surprisingly, the DRI of compound 






Compound (d9) is no longer a P-gp substrate and may overcome drug resistance 
To further investigate the mechanism of compound (d9) in overcoming drug 
resistance, we tested P-gp involvement for drug-resistance profile of our compounds. 
Because one of the mechanisms for drug resistance in cancer cells is due to the export of 
anticancer drug from cancer cells by P-gp transporter, and thus decreasing drug 
intracellular concentration. If a drug is a P-gp substrate, P-gp inhibitor (cyclosporine, 
CsA) will inhibit the drug export by P-gp, increase drug intracellular concentration, and 
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Figure 7. Cytotoxicity of Daunorubicin and compounds (D1, D2, D3, D5, D8, and 
D9) in drug resistant K562/dox cells in the absence and presence of CSA 
 
As shown in Figure 7, when CsA is used to inhibit drug export by P-gp, 
daunorubicin and most of its derivatives (compound dau, d1, d2, d3, d5, and d8) showed 
more than 2-fold increase for their cell killing effect. This indicates that these compounds 
are still P-gp substrates and may still exhibit drug resistance. However, CsA did not 
change the anticancer activity of our lead compound d9 in K562/R (Figure 7). This data 
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suggests that compound d9 is no longer a P-gp substrate and may therefore overcome 
drug resistance in cancer cells. 
 



































Figure 8. Anticancer activity of analogs in SW620 
 The results showed that the aglycon DNR-A exhibited 70- to 100-fold lower 
cytotoxicity than daunorubicin derivatives with various uncommon sugars. This suggests 
that sugar structure in daunorubicin plays a critical role in determining its anticancer 
activity.  
 Compound DNR-4 with 3’-OMe 2,6-dideoxy sugars showed very potent 
cytotoxicity with IC50 of 104 nM (Figure. 8). Importantly, compared to compounds 
DNR-2 and DNR-3 (with axial-3’-OMe or axial-3’-OH group), DNR-4 (with an 
equatorial-3’-OMe group) showed 10 to 20-fold higher anticancer activity. This 
suggested that the axial-3’-substitutent in sugar (such as in compounds DNR-2 and 
DNR-3) may interfere daunorubicin binding to DNA.  
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 Compound 1 and 5 with equatorial-4’-OH showed similar activity, while DNR-6 
(substituted 4’-OH with axial-4’-N3 in the sugar moiety), which is similar to aglycon 
DNR-A, lost its cytotoxicity (Fig 8). This suggests that 4-OH in the sugar may also be 
important for sugar containing anthracycline as an anticancer agent. Further SAR studies 
are required to clarify this finding. 
CONCLUSIONS 
 In summary, daunorubicin derivatives with α-linkage between two sugar units 
(d3) showed 35-fold higher anticancer activity than compound with β-linkage (d4). This 
indicates that α-linkage configuration was the mostly likely preferred conformation for 
the sugar moiety. Compounds with various terminal 2,6-dideoxy sugars (d1, d3, d5, and 
d8) showed 30 to 60-fold higher anticancer activity than compounds with terminal 2-
deoxy- or 6-deoxysugar (compound d6 and d7).  This suggests that 2”-OH or 6”-OH 
groups in terminal sugar decrease its anticancer activity.  Daunorubicin analog with 3’-
azido (d9) exhibited potent anticancer activity in both drug-sensitive and drug-resistant 
leukemia K562 cells. Compound (d9) showed significantly better anticancer activity than 
DNR in drug-resistant K562/Dox cells with 10-fold lower drug resistance index. P-gp 
inhibition by CsA confirmed that compound (d9) is no longer a P-glycoprotein (P-gp) 
substrate; therefore, compound (d9) may overcome P-gp-mediated drug resistance in 
cancer cells. Modifications of sugar moiety of the lead compound (d9) provide a practical 
approach to avert the recognition P-gp transporters, and thus overcome drug resistance. 
We are continuing to investigate the biological activities of compound (d9) in xenograft 
mouse models in vivo. Chemical modifications to optimize this series of compounds for 
SAR studies and improve their activity are currently in progress. Compound DNR-A 
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showed the lowest cytotoxicity (70 to 100-fold) compared to DNR, which further suggest 
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